Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxygen Biotherapeutics files request for designation of new wound care product
The RFD submission is part of a process with the FDA for determining which agency component will have primary jurisdiction for a drug, device or biological product. The
The RFD submission is part of a process with the FDA for determining which agency component will have primary jurisdiction for a drug, device or biological product. The
As BaroFold’s new president and CEO, Dr Freytag brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Dr Freytag served as chairman
The Peak surgery system includes the Pulsar generator and the Peak PlasmaBlade family of disposable, low-temperature surgical cutting and coagulation devices. The generator provides pulsed plasma radiofrequency energy
The minimum total value of these contracts is $650,000 and $210,000 respectively. These new orders bring the minimum total value of pharmaceutical clinical trial contracts secured by AtCor
Under the terms of the seven-year agreement, LeMaitre Vascular has exclusive rights to market and sell certain sizes of Neovasc’s tissue patch products used for vascular surgery in
Mr Billings is a founding partner at Atwater Financial Group, a Montreal-based financial consultancy group. Mr Billings is also the president and CEO of Orex Exploration, a junior
Already in partnership with Novartis since 2003 in the area of hypertension, with the co-marketing in France of Nisis and Nisisco, Ipsen’s new agreement strengthens the commitment of
Approximately 80 patients were enrolled to this study, randomized into two groups treated with 1mg of CF101 and placebo. Patients are taking the drug for 12 weeks plus
Tibion has developed the PowerKnee, a wearable bionic device for the leg which actively and transparently supplements muscle strength. To achieve licensure, Tibion demonstrated compliance with the federal
For the fourth quarter of 2008, Pfizer posted net income of $266 million, a decline of 90% compared with the prior-year quarter, and reported diluted earnings per share